BOEHRINGER-INGELHEIM
14.9.2020 14:03:10 CEST | Business Wire | Press release
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrated BI 425809 has met its primary endpoint. The data showed improvement in cognition in stable adult patients with schizophrenia.1 Central to many everyday tasks, impairment of cognitive function still constitutes a major burden for patients, and no pharmacological treatments are currently approved for cognitive impairment associated with schizophrenia (CIAS). These results presented at the 33rd European College of Neuropsychopharmacology (ECNP) Congress will advance the understanding of how deficits in transmission of signals between nerve cells may contribute to diminishing cognition in people living with schizophrenia.2
The Gly-T1 inhibitor, BI 425809, forms a key component of Boehringer Ingelheim’s Central Nervous System (CNS) research program. The latest trial results, along with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, will help determine the direction for BI 425809 in further schizophrenia research.3,4
Prof. W. Wolfgang Fleischhacker, Medical University Innsbruck, Austria: “The outcome of this trial is an important step forward in our understanding of cognition in schizophrenia. Cognitive impairment causes significant challenges for people in their everyday functioning. Patients with schizophrenia struggle with remembering things like birthdays, learning new tasks, concentrating, or making decisions that affect their everyday life. Advancing our understanding of how we might improve these symptoms in schizophrenia is significant for the research community and the patients and families living with this condition.”
The Phase II results of BI 425809 in cognitive impairment associated with schizophrenia are being further evaluated to assess how they will support the continued research and development for the treatment of schizophrenia.
“The trial results for our investigational compound BI 425809 in schizophrenia are encouraging. This is a positive advancement in our mechanistic knowledge of how excitatory neurotransmissions affect aspects of mental illness, aligning with our systematic neurobiological approach to CNS research,” adds Dr Vikas Mohan Sharma, M.D., head of medicine CNS, Retinopathies & Emerging Areas, Boehringer Ingelheim. “We recognize this is important news for people affected by schizophrenia. We are making progress in developing treatments which will not only reveal important advances in our understanding of schizophrenia but also potentially other neuropsychiatric diseases.”
Cognition is a fundamental aspect of everyday life, including problem solving, memory and attention. When affected, people living with poor cognition can have a reduced mental ability to process information, remember straightforward things or perceive other people’s emotions and expressions. These functions are common to many forms of mental disorders such as schizophrenia, Alzheimer’s disease and depression. Finding solutions for cognitive impairment is a key area of Boehringer Ingelheim CNS research.
~ENDS~
For references and notes to editiors, please visit: http://www.boehringer-ingelheim.com/press-release/phase-ii-results-cognitive-impairment-schizophrenia
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005477/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership3.8.2026 15:00:00 CEST | Press release
EuroTeleSites, one of Central and Eastern Europe's leading independent tower companies, today announced the results of its first year in partnership with Sitetracker, the leading global Asset Lifecycle Management platform. One year into the deployment, EuroTeleSites reports meaningful progress in its digital transformation, with measurable improvements in operational efficiency, cross-market transparency, and project coordination across its six-country footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727009809/en/ EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership Driving Efficiency in a Complex, High-Investment Environment EuroTeleSites invests approximately 25% of its revenue into capital expenditures in 2026, funding the construction and upgrade of tower infrastructure across Central and Eastern European markets. Managing this level of scale and complexity demands robust digital support
Visa to Acquire BioCatch3.8.2026 14:30:00 CEST | Press release
BioCatch’s behavioral and device intelligence expertise expected to help detect scams, account takeovers and digital fraud before they happen Visa (NYSE: V) today announced it has signed a definitive agreement to acquire BioCatch, a leading provider of behavioral-first, multi-signal fraud intelligence, from funds advised by Permira and other shareholders for $2.4 billion in cash. The acquisition of BioCatch complements Visa’s existing cyber, fraud, risk and security solutions and is expected to help clients better protect themselves and their customers from the growing threat of account takeovers, scams, money mules and application fraud. Since its inception, BioCatch has developed innovative AI and machine learning-based solutions that analyze thousands of application, behavioral, device, and network signals—such as keystrokes, touch gestures, and device handling—to detect fraud and distinguish legitimate users from fraudsters in real time. BioCatch protects 1.8 billion devices and 76
U.S. Bank Investment Services enhances investor and client onboarding experience for alternative investments3.8.2026 14:16:00 CEST | Press release
U.S. Bank Investment Services today announced it has gone live with a new client lifecycle management (CLM) platform, providing a comprehensive onboarding solution for alternative investment clients and the investors in their funds. The implementation is a key milestone in Investment Services’ multi-phased technology transformation strategy, aimed at modernizing processes, workflows and reporting across the private funds space. U.S. Bank leverages CLM provider Fenergo and its Fen-X platform. Fen-X automates many of the manual processes traditionally associated with underlying investors and direct client relationships and accelerates account setup while maintaining regulatory requirements. The enhanced onboarding experience provides investors and clients with more transparency throughout the process and enables integration with other solutions providers involved in the investor journey, such as screening and tax reporting. The investor experience has been further enhanced with an invest
Thales Launches Imperva for AWS to Help Organizations Protect Applications and APIs3.8.2026 14:00:00 CEST | Press release
Imperva for AWS delivers enterprise-grade web application, API, and bot protection for AWS environments Using Amazon CloudFront, AWS's fully managed content delivery network, to simplify deployment while strengthening application security Reduces operational complexity with centralized security visibility and policy management across AWS and multi-cloud environments Thales today announced the availability of Imperva for AWS, bringing its industry-leading web application firewall (WAF) to Amazon Web Services, Inc. (AWS) Marketplace as a SaaS offering. Built on key AWS services, Imperva for AWS helps organizations protect web applications and APIs against common cyber threats and malicious bot activity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803503864/en/ ©Thales The 2026 Thales Bad Bot Report found that automated traffic now accounts for 53% of all internet requests, with 27% of bot attacks targeting APIs directly.
MEX Exchange, Part of MultiBank Group Strengthens Leadership Team with Key Appointment3.8.2026 13:39:00 CEST | Press release
MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803009139/en/ MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. With more than 20 years of experience across sales, business development and electronic trading, Bahuguna joins MEX Exchange with extensive expertise in electronic trading solutions spanning EMS, OMS, OTC and ECN technologies across the foreign exchange
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom